Pfizer extends drug development agreement with Durham-based Icagen
Get the latest news alerts: Follow LTW at Twitter.
Local Tech Wire
DURHMA, N.C. - Icagen (Nasdaq: ICGN) will continue development of a potential new pain reliever in partnership with Pfizer under a one-year contract extension.
The companies are exploring and developing compounds that utilize sodium ion channels.
Pfizer will commit another $5 million in funding to Icagen. The companies have already been working together for two years. The revised contract also includes formation of a joint research committee.
The sodium channels are part of electrical signals in nerve fibers.
If the partnership produces approved products, Icagen could receive as much as $359 million for achieving development, regulatory and commercialization milestones for each product. Icagen also would receive royalties.
"We have made substantial progress over the first two years of our collaboration and look forward to working with Icagen in the upcoming year in seeking to identify drug candidates from these targeted programs,” said Gillian Burgess, chief scientific officer of Pfizer’s Pain Research Unit, in a statement.
Featured
Hot Off The Wire
- Red Hat's new Fedora lead; Cree LED breakthrough; Google, Cisco top 'green' list; Oracle rejects SAP settlement; Yahoo board shakeup
- Will Cisco report progress in its turnaround efforts?
- Cisco server fire threat; Lenovo Android upgrade; cloud startup vs. Cisco; Epic's Blesinski to host awards; Google 'Solve for X'
E-mail Preferences
The Skinny
- Charlotte's startup efforts pick up steam as more data pours in
- 'Battle in Bay 7' returns - Are you techies ready for some basketball?
- Inside RTP's new angel fund: Founders meeting 'significant' need
- Who won 'Social Bowl'? Super Bowl ads paying fans to play
- RTP broadband firm Overture, minus two top execs, launches new look
- Will RTP-based ChannelAdvisor go public? They're thinking
- What brands are winning Super Bowl hype? Two Durham firms to find out
- In Super Bowl of social media, Patriots win, Triangle firm says
- Big job cuts coming at IBM? Don't be surprised
- Erskine Bowles is among those who can cash in big time on Facebook IPO